Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
Article has an altmetric score of 3

See more details

Referenced in 5 patents
43 readers on Mendeley
  • Article usage
  • Citations to this article (230)

Advertisement

Research Article Free access | 10.1172/JCI115748

Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia.

E Fischer, M A Marano, K J Van Zee, C S Rock, A S Hawes, W A Thompson, L DeForge, J S Kenney, D G Remick, and D C Bloedow

Department of Surgery, Cornell University Medical College, New York 10021.

Find articles by Fischer, E. in: PubMed | Google Scholar

Department of Surgery, Cornell University Medical College, New York 10021.

Find articles by Marano, M. in: PubMed | Google Scholar

Department of Surgery, Cornell University Medical College, New York 10021.

Find articles by Van Zee, K. in: PubMed | Google Scholar

Department of Surgery, Cornell University Medical College, New York 10021.

Find articles by Rock, C. in: PubMed | Google Scholar

Department of Surgery, Cornell University Medical College, New York 10021.

Find articles by Hawes, A. in: PubMed | Google Scholar

Department of Surgery, Cornell University Medical College, New York 10021.

Find articles by Thompson, W. in: PubMed | Google Scholar

Department of Surgery, Cornell University Medical College, New York 10021.

Find articles by DeForge, L. in: PubMed | Google Scholar

Department of Surgery, Cornell University Medical College, New York 10021.

Find articles by Kenney, J. in: PubMed | Google Scholar

Department of Surgery, Cornell University Medical College, New York 10021.

Find articles by Remick, D. in: PubMed | Google Scholar

Department of Surgery, Cornell University Medical College, New York 10021.

Find articles by Bloedow, D. in: PubMed | Google Scholar

Published May 1, 1992 - More info

Published in Volume 89, Issue 5 on May 1, 1992
J Clin Invest. 1992;89(5):1551–1557. https://doi.org/10.1172/JCI115748.
© 1992 The American Society for Clinical Investigation
Published May 1, 1992 - Version history
View PDF
Abstract

The present study was undertaken to evaluate the extent to which an endogenous interleukin-1 (IL-1) response contributes to the hemodynamic and metabolic consequences of sublethal endotoxemia or lethal Gram-negative septic shock. Young, healthy baboons received either a sublethal dose of lipopolysaccharide (LPS) or an LD100 of live Escherichia coli bacteria, and one half of the animals in each group were continuously infused with IL-1 receptor antagonist (IL-1ra). Plasma IL-1 beta was not detected in this model of endotoxemia. Administration of IL-1ra had only minimal effects on the modest hemodynamic and metabolic responses to sublethal endotoxemia, and did not attenuate the plasma cytokine response. In contrast, high circulating levels of IL-1 beta (range 300-800 pg/ml) were seen during lethal E. coli septic shock. IL-1ra treatment significantly attenuated the decrease in mean arterial blood pressure (MAP) (from -72 +/- 8 to -43 +/- 6 mm Hg; P less than 0.05) and cardiac output (from -0.81 +/- 0.17 to -0.48 +/- 0.15 liter/min; P less than 0.05), and significantly improved survival from 43 to 100% at 24 h (P less than 0.05). The plasma IL-1 beta and IL-6 responses to lethal E. coli septic shock were also significantly diminished by IL-1ra treatment (P less than 0.05), whereas tumor necrosis factor-alpha (TNF alpha) concentrations were unaffected. We conclude that an exaggerated systemic IL-1 beta response is characteristic of lethal E. coli septic shock, and contributes significantly to the hemodynamic and metabolic consequences of E. coli septic shock. IL-1ra can significantly attenuate the cytokine cascade and improve survival.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1551
page 1551
icon of scanned page 1552
page 1552
icon of scanned page 1553
page 1553
icon of scanned page 1554
page 1554
icon of scanned page 1555
page 1555
icon of scanned page 1556
page 1556
icon of scanned page 1557
page 1557
Version history
  • Version 1 (May 1, 1992): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

Article has an altmetric score of 3
  • Article usage
  • Citations to this article (230)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Referenced in 5 patents
43 readers on Mendeley
See more details